Amniox¬ Medical is the leader in amniotic membrane and umbilical cord regenerative tissue therapies and is supported by more than 25 years of research characterizing and preserving the biology and functionality of human Amniotic Membrane (AM) and Umbilical Cord (UC). AM and UC are restorative tissues that carry unique regenerative properties and Amniox Medical is the sole provider of a matrix comprised of both human AM and UC. Our extensive research allows us to preserve and deliver the most functional allograft, transplanting the benefits of regenerative healing to adult wound environments.

As documented in more than 300 peer-reviewed publications, cryopreserved placental tissues have demonstrated the promotion of rapid regenerative healing while suppressing inflammation, scar formation and adhesion. Our patented CRYOTEK» preservation process maintains the innate biology and structural integrity of the natural tissue; protecting, preserving, and delivering the restorative properties of the AM/UC matrix.

Amniox Medical and Bio-Tissue, the global AM leader in ophthalmology, are technology partners with TissueTech, Inc., the developer of the innovative CRYOTEK technology. Bio-Tissue/Amniox Products have been implanted in humans in more than 130,000 cases with an excellent safety record.

NEOX¬ Wound Matrix is indicated for use as a wound covering for dermal ulcers and defects.

CLARIX¬ Regenerative Matrix is indicated for use as a surgical covering, wrap or barrier.

NEOX¬ FLO and CLARIX¬ FLO are the particulate forms of NEOX¬ wound matrix and CLARIX¬ regenerative matrix.